Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease

Effect of resveratrol on blood pressure: A meta-analysis of randomized controlled trials

(2015) Yanxia Liu et al.   CLINICAL NUTRITION

Population Pharmacokinetic Modeling of LY2189102 after Multiple Intravenous and Subcutaneous Administrations

(2014) Sébastien Bihorel et al.   AAPS Journal

Effect of resveratrol on glucose control and insulin sensitivity: a meta-analysis of 11 randomized controlled trials

(2014) Kai Liu et al.   AMERICAN JOURNAL OF CLINICAL NUTRITION

Effect of IL-6 on the insulin sensitivity in patients with type 2 diabetes

(2014) N. M. Harder-Lauridsen et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

The interleukin-1β modulator gevokizumab reduces neointimal proliferation and improves reendothelialization in a rat carotid denudation model

(2014) François Roubille et al.   ATHEROSCLEROSIS

mTOR inhibition: A promising strategy for stabilization of atherosclerotic plaques

(2014) Wim Martinet et al.   ATHEROSCLEROSIS

A phase II, randomized, placebo-controlled, double-blind, multi-dose study of SRT2104, a SIRT1 activator, in subjects with type 2 diabetes

(2014) Arun Baksi et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IL-6 in diabetes and cardiovascular complications

(2014) Dan Qu et al.   BRITISH JOURNAL OF PHARMACOLOGY

Interleukin 1β

(2014) Stephanie McCarty et al.   Cardiology in Review

CNX-012-570, a direct AMPK activator provides strong glycemic and lipid control along with significant reduction in body weight; studies from both diet-induced obese mice and db/db mice models

(2014) Tharappel M Anil et al.   Cardiovascular Diabetology

Safety and tolerability of canakinumab, an IL-1β inhibitor, in type 2 diabetes mellitus patients: a pooled analysis of three randomised double-blind studies

(2014) Campbell Howard et al.   Cardiovascular Diabetology

Anakinra treatment in patients with gout and type 2 diabetes

(2014) Antonio Vitale et al.   CLINICAL RHEUMATOLOGY

Pharmacokinetic and Pharmacodynamic Characteristics of Single-dose Canakinumab in Patients With Type 2 Diabetes Mellitus

(2014) Adele Noe et al.   CLINICAL THERAPEUTICS

Inflammation and Cardiovascular Disease: From Pathogenesis to Therapeutic Target

(2014) Enrica Golia et al.   Current Atherosclerosis Reports

Physiologic Versus Diabetogenic Effects of Interleukin-1: A Question of Weight

(2014) Hugo Besedovsky et al.   CURRENT PHARMACEUTICAL DESIGN

T Cell–Derived IL-22 Amplifies IL-1β–Driven Inflammation in Human Adipose Tissue: Relevance to Obesity and Type 2 Diabetes

(2014) Elise Dalmas et al.   DIABETES

Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: A critical reappraisal

(2014) A.J. Scheen et al.   DIABETES & METABOLISM

Resveratrol ameliorates diabetic vascular inflammation and macrophage infiltration in db/db mice by inhibiting the NF-κB pathway

(2014) Rong Guo et al.   Diabetes & Vascular Disease Research

Effect of Salsalate on Insulin Action, Secretion, and Clearance in Nondiabetic, Insulin-Resistant Individuals: A Randomized, Placebo-Controlled Study

(2014) Sun H. Kim et al.   DIABETES CARE

CCR2 antagonism in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study

(2014) N. A. Di Prospero et al.   DIABETES OBESITY & METABOLISM

The interleukin-1 receptor antagonist anakinra improves first-phase insulin secretion and insulinogenic index in subjects with impaired glucose tolerance

(2014) P. C. M. van Poppel et al.   DIABETES OBESITY & METABOLISM

Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes

(2014) Nathalie Esser et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Anti-inflammatory therapies for cardiovascular disease

(2014) P. M. Ridker et al.   EUROPEAN HEART JOURNAL

Gevokizumab in type 1 diabetes mellitus: extreme remedies for extreme diseases?

(2014) Kalliopi Pafili et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

NF-κB signaling at the crossroads of inflammation and atherogenesis: searching for new therapeutic links

(2014) Ioannis Pateras et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

From cytokine to myokine: the emerging role of interleukin-6 in metabolic regulation

(2014) Martin Pal et al.   IMMUNOLOGY AND CELL BIOLOGY

Effects of Resveratrol in Patients with Type 2 Diabetes Mellitus on Skeletal Muscle SIRT1 Expression and Energy Expenditure

(2014) Kian Peng Goh et al.   INTERNATIONAL JOURNAL OF SPORT NUTRITION AND EXERCISE METABOLISM

The Acute Effects of Low-Dose TNF-αon Glucose Metabolism andβ-Cell Function in Humans

(2014) Tobias Ibfelt et al.   MEDIATORS OF INFLAMMATION

Targeting inflammation in the treatment of type 2 diabetes: time to start

(2014) Marc Y. Donath   NATURE REVIEWS DRUG DISCOVERY

Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease

(2014)   NEW ENGLAND JOURNAL OF MEDICINE

Inflammation modulation and cardiovascular disease prevention

(2014) Zuhier Awan et al.   European Journal of Preventive Cardiology

Possible Role of Interleukin-1β in Type 2 Diabetes Onset and Implications for Anti-inflammatory Therapy Strategies

(2014) Gang Zhao et al.   PLoS Computational Biology

The Effect of Salsalate Therapy on Endothelial Function in a Broad Range of Subjects

(2014) Anju Nohria et al.   Journal of the American Heart Association

Resveratrol Levels and All-Cause Mortality in Older Community-Dwelling Adults

(2014) Richard D. Semba et al.   JAMA Internal Medicine

A54: Insulin Sensitivity Is Improved in sJIA Children With Insulin Resistance After Tocilizumab Treatment: Results From the TENDER Study

(2014) Hoda Mirjafari et al.   Arthritis & Rheumatology

Rationale and design of the Cardiovascular Inflammation Reduction Trial: A test of the inflammatory hypothesis of atherothrombosis

(2013) Brendan M. Everett et al.   AMERICAN HEART JOURNAL

Resveratrol: Therapeutic Potential for Improving Cardiometabolic Health

(2013) R. M. Pollack et al.   AMERICAN JOURNAL OF HYPERTENSION

The Effects of Salsalate on Glycemic Control in Patients With Type 2 Diabetes

(2013) Allison B. Goldfine   ANNALS OF INTERNAL MEDICINE

Salicylate (Salsalate) in Patients With Type 2 Diabetes

(2013) Allison B. Goldfine   ANNALS OF INTERNAL MEDICINE

Inhibition of the mTOR pathway: A possible protective role in coronary artery disease

(2013) Giovanni Tarantino et al.   ANNALS OF MEDICINE

Therapeutic potential of resveratrol in obesity and type 2 diabetes: new avenues for health benefits?

(2013) Silvie Timmers et al.   Annals of the New York Academy of Sciences

Inflammation in Obesity and Diabetes: Islet Dysfunction and Therapeutic Opportunity

(2013) Marc Y. Donath et al.   Cell Metabolism

Antagonistic crosstalk between NF-κB and SIRT1 in the regulation of inflammation and metabolic disorders

(2013) Anu Kauppinen et al.   CELLULAR SIGNALLING

Inflammasome and cytokine blocking strategies in autoinflammatory disorders

(2013) Monika Moll et al.   CLINICAL IMMUNOLOGY

Sirtuins as Possible Drug Targets in Type 2 Diabetes

(2013) Munehiro Kitada et al.   CURRENT DRUG TARGETS

Administration of IL-1 Trap prolongs survival of transplanted pancreatic islets to type 1 diabetic NOD mice

(2013) Tobias Rydgren et al.   CYTOKINE

Type 2 Diabetes Mellitus

(2013) Thomas Mandrup-Poulsen   DERMATOLOGIC CLINICS

Circulating Inflammatory Markers and the Risk of Vascular Complications and Mortality in People With Type 2 Diabetes and Cardiovascular Disease or Risk Factors: The ADVANCE Study

(2013) G. Lowe et al.   DIABETES

AMPK: A Target for Drugs and Natural Products With Effects on Both Diabetes and Cancer

(2013) D. G. Hardie   DIABETES

Impact of interleukin-1β antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: Results of secondary endpoints from a randomized, placebo-controlled trial

(2013) J. Hensen et al.   DIABETES & METABOLISM

The Impact of Salsalate Treatment on Serum Levels of Advanced Glycation End Products in Type 2 Diabetes

(2013) Joshua I. Barzilay et al.   DIABETES CARE

Targeting Inflammation Using Salsalate in Patients With Type 2 Diabetes: Effects on Flow-Mediated Dilation (TINSAL-FMD)

(2013) A. B. Goldfine et al.   DIABETES CARE

Double-Blind, Randomized Study Evaluating the Glycemic and Anti-inflammatory Effects of Subcutaneous LY2189102, a Neutralizing IL-1  Antibody, in Patients With Type 2 Diabetes

(2013) J. Sloan-Lancaster et al.   DIABETES CARE

Interaction between cytokines and inflammatory cells in islet dysfunction, insulin resistance and vascular disease

(2013) Y. Imai et al.   DIABETES OBESITY & METABOLISM

Targeting inflammation in the treatment of type 2 diabetes

(2013) M. Y. Donath   DIABETES OBESITY & METABOLISM

Targeting gp130 to prevent inflammation and promote insulin action

(2013) M. J. Kraakman et al.   DIABETES OBESITY & METABOLISM

Association between low SIRT1 expression in visceral and subcutaneous adipose tissues and metabolic abnormalities in women with obesity and type 2 diabetes

(2013) Young Sook Song et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance

(2013) A. B. Goldfine et al.   DIABETOLOGIA

Obesity phenotype is related to NLRP3 inflammasome activity and immunological profile of visceral adipose tissue

(2013) Nathalie Esser et al.   DIABETOLOGIA

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

(2013)   EUROPEAN HEART JOURNAL

Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis

(2013) S. Kaptoge et al.   EUROPEAN HEART JOURNAL

Emerging anti-inflammatory drugs for atherosclerosis

(2013) Jeremy P Berman et al.   EXPERT OPINION ON EMERGING DRUGS

AMPK, insulin resistance, and the metabolic syndrome

(2013) Neil B. Ruderman et al.   JOURNAL OF CLINICAL INVESTIGATION

Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future

(2013) Steven E Kahn et al.   LANCET

Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes

(2013) Timothy J. Sullivan et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus

(2013) Stefan Kiechl et al.   NATURE MEDICINE

XOMA 052, an anti-IL-1β monoclonal antibody, prevents IL-1β-mediated insulin resistance in 3T3-L1 adipocytes

(2013) Masahisa Handa et al.   Obesity

Novel Small-Molecule AMP-Activated Protein Kinase Allosteric Activator with Beneficial Effects in db/db Mice

(2013) Li-Na Zhang et al.   PLoS One

Evidence for a Common Mechanism of SIRT1 Regulation by Allosteric Activators

(2013) B. P. Hubbard et al.   SCIENCE

Anti-Inflammatory Therapy in Chronic Disease: Challenges and Opportunities

(2013) I. Tabas et al.   SCIENCE

AMPK: mediating the metabolic effects of salicylate-based drugs?

(2013) Gregory R. Steinberg et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Cardiovascular Effects of a Novel SIRT1 Activator, SRT2104, in Otherwise Healthy Cigarette Smokers

(2013) Sowmya Venkatasubramanian et al.   Journal of the American Heart Association

Mechanisms of disease: inflammasome activation and the development of type 2 diabetes

(2013) Ryan W. Grant et al.   Frontiers in Immunology

Sirtuin-1 is a nutrient-dependent modulator of inflammation

(2013) Maya E. Kotas et al.   Adipocyte

How biologics targeting the IL-1 system are being considered for the treatment of type 2 diabetes

(2012) Marianne Böni-Schnetzler et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

The Inflammasome Puts Obesity in the Danger Zone

(2012) Rinke Stienstra et al.   Cell Metabolism

Effects of Interleukin-1β Inhibition With Canakinumab on Hemoglobin A1c, Lipids, C-Reactive Protein, Interleukin-6, and Fibrinogen

(2012) Paul M Ridker et al.   CIRCULATION

Interleukin-1 (IL-1) family of cytokines: Role in Type 2 Diabetes

(2012) Monisha Banerjee et al.   CLINICA CHIMICA ACTA

Pharmacokinetic and Pharmacodynamic Properties of Canakinumab, a Human Anti-Interleukin-1β Monoclonal Antibody

(2012) Abhijit Chakraborty et al.   CLINICAL PHARMACOKINETICS

Effects of Gevokizumab on Glycemia and Inflammatory Markers in Type 2 Diabetes

(2012) C. Cavelti-Weder et al.   DIABETES CARE

Effect of anti-IL-1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial

(2012) A. Rissanen et al.   DIABETES OBESITY & METABOLISM

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETOLOGIA

Reduction of Insulin Resistance and Plasma Glucose Level by Salsalate Treatment in Persons with Prediabetes

(2012) Elham Faghihimani et al.   Endocrine Practice

Novel directions for diabetes mellitus drug discovery

(2012) Kenneth Maiese et al.   Expert Opinion on Drug Discovery

Exploiting the anti-inflammatory effects of AMP-activated protein kinase activation

(2012) Ian P Salt et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Direct AMP-activated protein kinase activators: a review of evidence from the patent literature

(2012) Fabrizio Giordanetto et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Inflammation links excess fat to insulin resistance: the role of the interleukin-1 family

(2012) Cees J. Tack et al.   IMMUNOLOGICAL REVIEWS

Molecular Targets Related to Inflammation and Insulin Resistance and Potential Interventions

(2012) Sandro M. Hirabara et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

One Target—Two Different Binding Modes: Structural Insights into Gevokizumab and Canakinumab Interactions to Interleukin-1β

(2012) Michaela Blech et al.   JOURNAL OF MOLECULAR BIOLOGY

Low-Dose Colchicine for Secondary Prevention of Cardiovascular Disease

(2012) Stefan M. Nidorf et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies

(2012)   LANCET

The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis

(2012)   LANCET

Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases

(2012) Charles A. Dinarello et al.   NATURE REVIEWS DRUG DISCOVERY

A Pilot Randomized, Placebo Controlled, Double Blind Phase I Trial of the Novel SIRT1 Activator SRT2104 in Elderly Volunteers

(2012) Vincenzo Libri et al.   PLoS One

The Ancient Drug Salicylate Directly Activates AMP-Activated Protein Kinase

(2012) S. A. Hawley et al.   SCIENCE

The role of inflammation and cardiovascular disease risk on microvascular and macrovascular endothelial function in patients with rheumatoid arthritis: a cross-sectional and longitudinal study

(2012) Aamer Sandoo et al.   ARTHRITIS RESEARCH & THERAPY

Anti-tumor necrosis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistance

(2012) Ilias Stagakis et al.   ARTHRITIS RESEARCH & THERAPY

Salsalate improves glycemic control in patients with newly diagnosed type 2 diabetes

(2011) Elham Faghihimani et al.   ACTA DIABETOLOGICA

Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: Rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)

(2011) Paul M Ridker et al.   AMERICAN HEART JOURNAL

Systematic Review and Meta-Analysis of Methotrexate Use and Risk of Cardiovascular Disease

(2011) Renata Micha et al.   AMERICAN JOURNAL OF CARDIOLOGY

Small-Molecule Allosteric Activators of Sirtuins

(2011) David A. Sinclair et al.   Annual Review of Pharmacology and Toxicology

A pilot study of endothelial dysfunction and aortic stiffness after interleukin-6 receptor inhibition in rheumatoid arthritis

(2011) A.D. Protogerou et al.   ATHEROSCLEROSIS

SirT1 Regulates Adipose Tissue Inflammation

(2011) M. P. Gillum et al.   DIABETES

Inhibition of IL-1  Improves Fatigue in Type 2 Diabetes

(2011) C. Cavelti-Weder et al.   DIABETES CARE

Novel C-C chemokine receptor 2 antagonists in metabolic disease: a review of recent developments

(2011) Young Sun Kang et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Systemic Blockade of TNF-α does not Improve Insulin Resistance in Humans

(2011) I. Ferraz-Amaro et al.   HORMONE AND METABOLIC RESEARCH

Association Between Disease-Modifying Antirheumatic Drugs and Diabetes Risk in Patients With Rheumatoid Arthritis and Psoriasis

(2011) Daniel H. Solomon   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Treatment with Anakinra Improves Disposition Index But Not Insulin Sensitivity in Nondiabetic Subjects with the Metabolic Syndrome: A Randomized, Double-Blind, Placebo-Controlled Study

(2011) Edwin J. P. van Asseldonk et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling

(2011) Simon A. Jones et al.   JOURNAL OF CLINICAL INVESTIGATION

Management of type 2 diabetes: new and future developments in treatment

(2011) Abd A Tahrani et al.   LANCET

Diabetes mellitus risk in rheumatoid arthritis: Reduced incidence with anti-tumor necrosis factor α therapy

(2011) Jana l. Antohe et al.   ARTHRITIS CARE & RESEARCH

Role of IL-1β in type 2 diabetes

(2011) Charles A Dinarello et al.   Current Opinion in Endocrinology Diabetes and Obesity

AMPK and SIRT1: a long-standing partnership?

(2010) Neil B. Ruderman et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Potential Role of Salicylates in Type 2 Diabetes

(2010) Martha M Rumore et al.   ANNALS OF PHARMACOTHERAPY

Insulin resistance in rheumatoid arthritis: the impact of the anti-TNF-α therapy

(2010) Miguel A. Gonzalez-Gay et al.   Annals of the New York Academy of Sciences

Improvement of HbA1c during treatment with humanised anti-interleukin 6 receptor antibody, tocilizumab

(2010) A. Ogata et al.   ANNALS OF THE RHEUMATIC DISEASES

Infliximab and insulin resistance

(2010) Francesco Ursini et al.   AUTOIMMUNITY REVIEWS

Leptin and mTOR: Partners in metabolism and inflammation

(2010) Clarissa Maya-Monteiro et al.   CELL CYCLE

Potential Effect of Anti-Tumour Necrosis Factor-Alpha Treatment on Reducing the Cardiovascular Risk Related to Rheumatoid Arthritis

(2010) Massimo Cugno et al.   Current Vascular Pharmacology

TNF-α Antagonism with Etanercept Decreases Glucose and Increases the Proportion of High Molecular Weight Adiponectin in Obese Subjects with Features of the Metabolic Syndrome

(2010) Takara L. Stanley et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Inflammation and Microvascular and Macrovascular Endothelial Dysfunction in Rheumatoid Arthritis: Effect of Treatment

(2010) W. FOSTER et al.   JOURNAL OF RHEUMATOLOGY

AMPK and vasculoprotection

(2010) Marie-Ann Ewart et al.   PHARMACOLOGY & THERAPEUTICS

Effects of Inhibition of Interleukin-6 Signalling on Insulin Sensitivity and Lipoprotein (A) Levels in Human Subjects with Rheumatoid Diseases

(2010) Olaf Schultz et al.   PLoS One

SIRT1 inhibits inflammatory pathways in macrophages and modulates insulin sensitivity

(2009) Takeshi Yoshizaki et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Immunological and Inflammatory Functions of the Interleukin-1 Family

(2009) Charles A. Dinarello   Annual Review of Immunology

Does TNF-alpha blockade play any role in cardiovascular risk among rheumatoid arthritis (RA) patients?

(2009) Raquel Cuchacovich et al.   CLINICAL RHEUMATOLOGY

Role of TNF-α in vascular dysfunction

(2009) Hanrui Zhang et al.   CLINICAL SCIENCE

Effects of tumor necrosis factor-α blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis

(2009) Jennifer Channual et al.   Dermatologic Therapy

AMP-Activated Protein Kinase-Deficient Mice Are Resistant to the Metabolic Effects of Resveratrol

(2009) J.-H. Um et al.   DIABETES

Sustained Effects of Interleukin-1 Receptor Antagonist Treatment in Type 2 Diabetes

(2009) C. M. Larsen et al.   DIABETES CARE

Effects of infliximab therapy on abdominal fat and metabolic profile in patients with Crohnʼs disease

(2009) Erika Parmentier-Decrucq et al.   INFLAMMATORY BOWEL DISEASES

Inflammation in Atherosclerosis

(2009) Peter Libby et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Everolimus, a promising medical therapy for coronary heart disease?

(2009) Lei Jia et al.   MEDICAL HYPOTHESES

Use of Salsalate to Target Inflammation in the Treatment of Insulin Resistance and Type 2 Diabetes

(2008) Allison B. Goldfine et al.   CTS-Clinical and Translational Science

The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study

(2008) J. Koska et al.   DIABETOLOGIA

Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs

(2008) J Avouac et al.   EXPERT OPINION ON PHARMACOTHERAPY